CA2453173C - Mycobacterial antigens expressed during latency - Google Patents

Mycobacterial antigens expressed during latency Download PDF

Info

Publication number
CA2453173C
CA2453173C CA2453173A CA2453173A CA2453173C CA 2453173 C CA2453173 C CA 2453173C CA 2453173 A CA2453173 A CA 2453173A CA 2453173 A CA2453173 A CA 2453173A CA 2453173 C CA2453173 C CA 2453173C
Authority
CA
Canada
Prior art keywords
ala
leu
val
gly
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2453173A
Other languages
English (en)
French (fr)
Other versions
CA2453173A1 (en
Inventor
Brian William James
Philip Marsh
Tobias Hampshire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Health
Original Assignee
UK Secretary of State for Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116385A external-priority patent/GB0116385D0/en
Priority claimed from GB0123993A external-priority patent/GB0123993D0/en
Application filed by UK Secretary of State for Health filed Critical UK Secretary of State for Health
Publication of CA2453173A1 publication Critical patent/CA2453173A1/en
Application granted granted Critical
Publication of CA2453173C publication Critical patent/CA2453173C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2453173A 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency Expired - Fee Related CA2453173C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0116385A GB0116385D0 (en) 2001-07-04 2001-07-04 Mycobacterial antigens expressed during latency
GB0116385.6 2001-07-04
GB0123993A GB0123993D0 (en) 2001-10-05 2001-10-05 Mycobacterial antigens expressed during latency
GB0123993.8 2001-10-05
PCT/GB2002/003052 WO2003004520A2 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Publications (2)

Publication Number Publication Date
CA2453173A1 CA2453173A1 (en) 2003-01-16
CA2453173C true CA2453173C (en) 2013-12-10

Family

ID=26246282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2453173A Expired - Fee Related CA2453173C (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Country Status (6)

Country Link
US (3) US7393540B2 (enExample)
EP (2) EP2196473A1 (enExample)
JP (1) JP2005508613A (enExample)
AU (2) AU2002314358C1 (enExample)
CA (1) CA2453173C (enExample)
WO (1) WO2003004520A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7393539B2 (en) 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
EP1523331B1 (en) * 2002-07-13 2013-02-27 Statens Serum Institut Therapeutic tb vaccine
WO2004067718A2 (en) * 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
WO2006104389A1 (en) * 2005-03-31 2006-10-05 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
CA2606962A1 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
AU2006261445B2 (en) * 2005-06-23 2011-03-31 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
EP1913020B1 (en) * 2005-08-09 2010-05-05 HAV Vaccines Limited Immunogenic constructs
US7601357B2 (en) * 2005-12-07 2009-10-13 University Of Central Florida Research Foundation, Inc. Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment
CN101374964B (zh) * 2005-12-09 2013-07-17 贝勒研究院 外周血液白细胞转录模式的模块水平分析
NZ597557A (en) * 2006-03-02 2013-10-25 Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
MX2010014556A (es) * 2008-06-25 2011-07-28 Baylor Res Inst Firma transcripcional de sangre por infeccion de mycobacterium tuberculosis.
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
PL2661253T3 (pl) 2011-01-04 2017-08-31 Archivel Farma, Sl Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2012138754A2 (en) * 2011-04-04 2012-10-11 Beth Israel Deaconess Medical Center, Inc. Mycobacterial vaccine vectors and methods of using the same
WO2013033363A1 (en) * 2011-08-30 2013-03-07 The Uab Research Foundation Mycobacterium tuberculosis porins and toxins and related methods
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
US10357555B2 (en) 2012-07-10 2019-07-23 Transgene Sa Mycobacterial antigen vaccine
US10197560B2 (en) 2013-06-27 2019-02-05 The Brigham And Women's Hospital, Inc. Methods and systems for determining M. tuberculosis infection
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
EP3180353B1 (en) * 2014-08-15 2021-09-22 Oxford Immunotec Limited Mycobacterium tuberculosis proteins
CN108267588B (zh) * 2016-12-30 2020-10-23 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途
US12234464B2 (en) 2018-11-09 2025-02-25 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides
CN110129465B (zh) * 2019-05-22 2023-08-22 杭州优思达生物技术股份有限公司 一种海分枝杆菌核酸的快速检测方法及其试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DE4221858A1 (de) 1992-07-03 1994-01-05 Becker Carl Chemie Gmbh Addukte von 0,0-Dialkyldithiophosphorsäuren an ungesättigte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schmiermitteladditive
US6583266B1 (en) * 1993-08-19 2003-06-24 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics
US5783386A (en) 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
KR100445103B1 (ko) 1994-12-09 2004-12-04 임페리얼 컬리지 이노베이션스 리미티드 유전자의동정
US6572865B1 (en) * 1995-06-15 2003-06-03 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides and methods for using same
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
CA2197524A1 (en) * 1996-02-22 1997-08-22 Bradley Stuart Dehoff Polyketide synthase genes
EP0910403A1 (en) 1996-03-27 1999-04-28 The Johns-Hopkins University Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
IL129389A0 (en) 1996-10-11 2000-02-17 Corixa Corp Compounds and methods for diagnsosis of tuberculosis
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711389D0 (en) 1997-06-04 1997-07-30 Univ Wales The Bacterial pheromones and uses therefor
EP1003870A1 (en) 1997-07-16 2000-05-31 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
AU9200398A (en) 1997-08-22 1999-03-16 Yale University A process to study changes in gene expression in granulocytic cells
GB9723630D0 (en) 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
US6183957B1 (en) 1998-04-16 2001-02-06 Institut Pasteur Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria
EP1075485A4 (en) 1998-05-05 2004-12-15 Gene Logic Inc METHOD FOR STUDYING MODIFICATIONS OF GENE EXPRESSION IN T CELLS
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
GB9904773D0 (en) 1999-03-02 1999-04-28 Microbiological Res Authority Culture of mycobacteria
US6573361B1 (en) * 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US7393539B2 (en) * 2001-06-22 2008-07-01 Health Protection Agency Mycobacterial antigens expressed under low oxygen tension
EP2196473A1 (en) * 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency

Also Published As

Publication number Publication date
US20090082296A1 (en) 2009-03-26
AU2002314358B2 (en) 2008-08-14
US7393540B2 (en) 2008-07-01
JP2005508613A (ja) 2005-04-07
US20040241826A1 (en) 2004-12-02
EP2196473A1 (en) 2010-06-16
AU2002314358C1 (en) 2009-03-26
AU2008243118A1 (en) 2008-11-27
EP1404706A2 (en) 2004-04-07
WO2003004520A3 (en) 2003-10-16
US8003776B2 (en) 2011-08-23
WO2003004520A2 (en) 2003-01-16
US20120034689A1 (en) 2012-02-09
US8399650B2 (en) 2013-03-19
CA2453173A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
CA2453173C (en) Mycobacterial antigens expressed during latency
US8017753B2 (en) Mycobacterial antigens expressed under low oxygen tension
AU2002314358A1 (en) Mycobacterial antigens expressed during latency
US20110091881A1 (en) Mycobacterial genes down-regulated during latency
US20030147897A1 (en) M. tuberculosis antigens
US6641814B1 (en) Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
AU2002317940A1 (en) Mycobacterial antigens expressed under low oxygen tension
US20040115211A1 (en) TB diagnostic based on antigens from M. tuberculosis
AU2002336179A1 (en) Mycobacterial genes down-regulated during latency
US20040110269A1 (en) Protection against mycobacterial infections
WO2003033530A2 (en) Mycobacterial antigens expressed under high oxygen tension

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150706